1. What Happened at iCure?
iCure achieved sales of 25.2 billion KRW in H1 2025 but reported an operating loss of 4.4 billion KRW and a net loss of 9.8 billion KRW, failing to escape the red. Although sales exceeded market expectations of 0 KRW, the deteriorating profitability is a serious concern.
2. Why These Results?
iCure’s poor performance is primarily attributed to increased costs due to R&D investment in the pharmaceutical business and intensified competition in the cosmetics market. The high-interest rate environment is also adding to the financial burden. Despite a temporary return to profitability in Q3 2024, the company has consistently recorded losses, highlighting the urgent need for profitability improvement.
3. What’s Next for iCure?
iCure’s future stock price hinges on its ability to improve profitability. The company must enhance R&D investment efficiency, achieve success with new pipelines, and strengthen its competitiveness in the cosmetics business to restore its profit-generating capacity. Improving financial structure and regaining investor trust are also crucial tasks.
4. What Should Investors Do?
Investors should closely monitor iCure’s future IR activities and earnings announcements, carefully assessing the possibility of a real turnaround. Currently, the investment risk is very high, requiring a cautious approach.